The Conversation (0)
Nuvo Pharmaceuticals announced it entered into a license and distribution agreement with Gebro Pharma for the exclusive right to register, distribute, market and sell Pennsaid 2 percent in Switzerland and Liechtenstein.
Nuvo Pharmaceuticals (TSX:NRI; OTCQX:NRIFF) announced it entered into a license and distribution agreement with Gebro Pharma for the exclusive right to register, distribute, market and sell Pennsaid 2 percent in Switzerland and Liechtenstein.
As quoted in the press release:
Gebro Pharma AG is the Switzerland-based affiliate of Gebro Holding GmbH, an Austrian-based pharmaceutical company with a commercial presence via subsidiaries and partners in over 25 countries globally.
“We are extremely pleased to partner Pennsaid 2% with Gebro Pharma in Switzerland and Liechtenstein,” said Jesse Ledger, Nuvo’s President & CEO. “Gebro Pharma’s strong presence in rheumatology, pain and over-the-counter brands make it an ideal partner for Nuvo in this region. This transaction is an example of our ongoing progress towards making Pennsaid 2% a global brand.”
Click here to read the full press release.
Source: www.newswire.ca
